RP-HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-09. Anything still debated is marked as such rather than presented as settled.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Peptide chain coordinated to a single metal ion |
| CAS number | 89030-95-5 | Indexed for the peptide-copper complex |
| Molecular formula | C14H22CuN6O4 | Approximate formula for a one-to-one complex |
| Appearance | Blue to violet solid | Color from copper d-d transitions |
| Solubility class | Freely soluble in water | Also dispersible in some polar solvents |
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Drugs continue to be taken off the market due to late discovery of hepatotoxicity. Due to its unique metabolism and close relationship with the gastrointestinal tract, the liver is susceptible to injury from drugs and other substances. 75% of blood coming to the liver arrives directly from gastrointestinal organs and the spleen via portal veins that bring drugs and xenobiotics in near-undiluted form. Several mechanisms are responsible for either inducing hepatic injury or worsening the damage process. Many chemicals damage mitochondria, an intracellular organelle that produces energy. Its dysfunction releases excessive amount of oxidants that, in turn, injure hepatic cells. Activation of some enzymes in the cytochrome P-450 system such as CYP2E1 also lead to oxidative stress. Injury to hepatocyte and bile duct cells lead to accumulation of bile acid inside the liver. This promotes further liver damage. Non-parenchymal cells such as Kupffer cells, collagen-producing stellate cells, and leukocytes (i.e. neutrophil and monocyte) also have a role in the mechanism.
Artificial nucleic acid analogues have been designed and synthesized. They include peptide nucleic acid, morpholino- and locked nucleic acid, glycol nucleic acid, and threose nucleic acid. Each of these is distinguished from naturally occurring DNA or RNA by changes to the backbone of the molecules.
== Composition history == The original commission for Higdon to compose her first opera, in collaboration with Scheer as librettist, came from the San Francisco Opera. Over the period of 2009 to 2011, the creators had searched for various subjects to adapt, which led to the choice of the novel Cold Mountain. However, complications related to securing the rights to adapt the novel, along with conflicts over financial demands and reports of clashes of working style with San Francisco Opera with respect to the creation of new operas, led to the lapsing of this commission. Santa Fe Opera subsequently rescued this commission, in conjunction with the Opera Company of Philadelphia (now Opera Philadelphia) and the Minnesota Opera. Scheer began to write the libretto in autumn 2011, and Higdon began to compose the music in 2012. Higdon used her personal background of having lived in the Appalachia region of the US to assist Scheer with rendering portions of his libretto in a style of speech more authentic to the region, when needed: "I helped Gene 'southernize' the libretto. Gene's from New York, and he wasn't sure how to shape the language for the characters, so I took care of it. Those speech patterns felt very familiar. Scheer estimated that 20 to 25% of the sung text in his libretto came directly from lines in the novel. Higdon took 20 months to complete her score. Workshops of the opera at the Curtis Institute of Music occurred in December 2012 for act 1 and in December 2013 for act 2. In advance of the premiere, four of the five scheduled Santa Fe Opera performances sold out.
=== Glycerol intoxication === Excessive consumption by children can lead to glycerol intoxication. Symptoms of intoxication include hypoglycemia, nausea, and a loss of consciousness. While intoxication as a result of excessive glycerol consumption is rare and its symptoms generally mild, occasional reports of hospitalization have occurred. In the United Kingdom in August 2023, manufacturers of syrup used in slush ice drinks were advised to reduce the amount of glycerol in their formulations by the Food Standards Agency to reduce the risk of intoxication. A 2025 study reported that between 2018 and 2024, at least 21 children aged 2–7 in the UK and Ireland received emergency treatment for symptoms of glycerol intoxication following the consumption of slush ice drinks. Food Standards Scotland advises that slush ice drinks containing glycerol should not be given to children under the age of 4, owing to the risk of intoxication. It also recommends that businesses do not use free refill offers for the drinks in venues where children under the age of 10 are likely to consume them, and that products should be appropriately labelled to inform consumers of the presence of glycerol.
Sources: en.wikipedia.org
The vasopressins are peptides consisting of nine amino acids (nonapeptides). The amino acid sequence of arginine vasopressin (argipressin) is Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2, with the cysteine residues forming a disulfide bond and the C-terminus of the sequence converted to a primary amide. Lysine vasopressin (lypressin) has a lysine in place of the arginine as the eighth amino acid, and is found in pigs and some related animals, whereas arginine vasopressin is found in humans. The structure of oxytocin is very similar to that of the vasopressins: It is also a nonapeptide with a disulfide bridge and its amino acid sequence differs at only two positions. The two genes are located on the same chromosome separated by a relatively small distance of less than 15,000 bases in most species. The magnocellular neurons that secrete vasopressin are adjacent to magnocellular neurons that secrete oxytocin, and are similar in many respects. The similarity of the two peptides can cause some cross-reactions: oxytocin has a slight antidiuretic function, and high levels of AVP can cause uterine contractions. Comparison of vasopressin and oxytocin neuropeptide families:
Repatriating the survivors of the 16 October strike on a semi-submersible to their home countries for prosecution avoids a civilian court challenge to continued detention without evidence, and a military court challenge to the legal justification for treating prisoners as unlawful combatants if they were not engaged in armed conflict.
CGRP mediates its effects through a heteromeric receptor composed of a G protein-coupled receptor called calcitonin receptor-like receptor (CALCRL) and RAMP1. CGRP receptors are found throughout all the body, suggesting that the protein may modulate a variety of physiological functions in all major systems (e.g., respiratory, endocrine, gastrointestinal, immune, and cardiovascular). These transmembrane receptors form folded accordion-like structures embedded in the cell membrane with loops of protein on the inside (intracellular loops) and outside (extracellular loops) of the membrane. The second extracellular loop is fundamental for ligand-induced activation, with key interactions of R274/Y278/D280/W283.
Sources: en.wikipedia.org
It is the copper complex of the tripeptide glycyl-L-histidyl-lysine. The metal ion is held by the histidine imidazole group and the peptide N-terminus. Most research on it concerns skin and wound models.
The tripeptide was first isolated from human plasma and has also been reported in saliva and urine. Plasma levels appear to decline with age in some small studies. Those observations rest on limited sample sizes.
It is not authorized as a systemic medicine in most countries. Cosmetic preparations list it as an ingredient rather than an active pharmaceutical substance. Legal status therefore differs by jurisdiction.
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.